The relative lack of side effects is particularly important for those with recurring or chronic pain, as it lowers the risks associated with multiple injections
The Phase 2 and Phase 3 trials so far have shown a safety profile broadly consistent with other GLP-1 medications: gastrointestinal side effects are common, and a new signal called dysaesthesia (an abnormal skin sensation) appears more often at higher doses
GLP-1 therapy targets the appetite signals that willpower cannot, so your Premier Plaza plan finally answers the resistance you feel
This applies even more to populations at higher-relative risk such as the elderly, those with pre-existing PDR or prolonged DM, individuals on multiple medications for their diabetes, and those who experience rapid reductions in either body weight or blood glucose
Currently, only 13 states cover GLP-1s for weight loss, according to KFF